BioXcel Therapeutics, Inc. SEC filings BTAIQ
BioXcel Therapeutics, Inc. has 672 filings in SEC EDGAR's recent list, going back to Nov 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (acquisition or sale of assets, officer or director change, bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Mar 27, 2026 | — |
| 424B5 | Prospectus supplement | Mar 11, 2026 | — |
| 424B5 | Prospectus supplement | Aug 18, 2025 | — |
| 424B5 | Prospectus supplement | Aug 6, 2025 | — |
| S-8 | Employee stock plan registration | Apr 4, 2025 | — |
| 424B5 | Prospectus supplement | Apr 3, 2025 | — |
| 424B5 | Prospectus supplement | Mar 4, 2025 | — |
| S-3 | Shelf registration | Jan 10, 2025 | — |
| 424B5 | Prospectus supplement | Nov 25, 2024 | — |
| 424B5 | Prospectus supplement | Nov 21, 2024 | — |
| 424B7 | Filing | Jun 4, 2024 | — |
| S-8 | Employee stock plan registration | Apr 3, 2024 | — |
| 424B5 | Prospectus supplement | Mar 25, 2024 | — |
| 424B5 | Prospectus supplement | Feb 8, 2024 | — |
| S-3 | Shelf registration | Jan 12, 2024 | — |
| 424B5 | Prospectus supplement | Nov 14, 2023 | — |
| S-3 | Shelf registration | Nov 2, 2023 | — |
| S-8 | Employee stock plan registration | Mar 17, 2023 | — |
| S-8 | Employee stock plan registration | Aug 16, 2022 | — |
| S-3 | Shelf registration | May 27, 2022 | — |
| POS AM | Filing | Mar 11, 2022 | — |
| 424B5 | Prospectus supplement | Jun 24, 2021 | — |
| 424B5 | Prospectus supplement | Jun 22, 2021 | — |
| 424B5 | Prospectus supplement | May 10, 2021 | — |
| 424B5 | Prospectus supplement | Jul 30, 2020 | — |
| 424B5 | Prospectus supplement | Jul 27, 2020 | — |
| S-3ASR | Automatic shelf registration | Jul 27, 2020 | — |
| S-8 | Employee stock plan registration | May 21, 2020 | — |
| 424B5 | Prospectus supplement | Feb 21, 2020 | — |
| 424B5 | Prospectus supplement | Feb 19, 2020 | — |
| S-8 | Employee stock plan registration | Nov 26, 2019 | — |
| 424B5 | Prospectus supplement | Sep 27, 2019 | — |
| 424B5 | Prospectus supplement | Sep 25, 2019 | — |
| 424B5 | Prospectus supplement | May 20, 2019 | — |
| S-3 | Shelf registration | Apr 1, 2019 | — |
| S-3 | Shelf registration | Mar 14, 2019 | — |
| 424B4 | Prospectus | Mar 9, 2018 | — |
| FWP | Free writing prospectus | Mar 5, 2018 | — |
| S-1/A | Amended registration statement | Mar 5, 2018 | — |
| S-1/A | Amended registration statement | Feb 27, 2018 | — |
| S-1/A | Amended registration statement | Feb 26, 2018 | — |
| S-1 | Registration statement | Feb 12, 2018 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BTAIQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720893
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.